Compare ANL & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | GNTA |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 39.4M |
| IPO Year | 2023 | 2021 |
| Metric | ANL | GNTA |
|---|---|---|
| Price | $1.05 | $1.89 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 122.5K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.35 |
| 52 Week High | $2.99 | $10.00 |
| Indicator | ANL | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 40.49 |
| Support Level | $1.32 | $1.80 |
| Resistance Level | $1.59 | $2.20 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 1.69 | 59.77 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.